Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis.
Newsome PN, Sanyal AJ, Neff G, Schattenberg JM, Ratziu V, Ertle J, Link J, Mackie A, Schoelch C, Lawitz E; BI 1467335 NASH Phase IIa trial team. Newsome PN, et al. Among authors: schoelch c. Nat Commun. 2023 Nov 6;14(1):7151. doi: 10.1038/s41467-023-42398-w. Nat Commun. 2023. PMID: 37932258 Free PMC article. Clinical Trial.
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
Rasmussen DGK, Anstee QM, Torstenson R, Golding B, Patterson SD, Brass C, Thakker P, Harrison S, Billin AN, Schuppan D, Dufour JF, Andersson A, Wigley I, Shumbayawonda E, Dennis A, Schoelch C, Ratziu V, Yunis C, Bossuyt P, Karsdal MA. Rasmussen DGK, et al. Among authors: schoelch c. J Hepatol. 2023 Apr;78(4):852-865. doi: 10.1016/j.jhep.2022.11.028. Epub 2022 Dec 14. J Hepatol. 2023. PMID: 36526000 Free article. Review.
Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
Albach FN, Wagner F, Hüser A, Igel J, Joseph D, Hilbert J, Schoelch C, Padula SJ, Steffgen J. Albach FN, et al. Among authors: schoelch c. Eur J Clin Pharmacol. 2018 Feb;74(2):161-169. doi: 10.1007/s00228-017-2362-8. Epub 2017 Nov 10. Eur J Clin Pharmacol. 2018. PMID: 29127458 Free PMC article. Clinical Trial.
Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.
Schwabe C, Rosenstock B, Doan T, Hamilton P, Dunbar PR, Eleftheraki AG, Joseph D, Hilbert J, Schoelch C, Padula SJ, Steffgen J. Schwabe C, et al. Among authors: schoelch c. J Clin Pharmacol. 2018 Dec;58(12):1566-1577. doi: 10.1002/jcph.1278. Epub 2018 Aug 16. J Clin Pharmacol. 2018. PMID: 30113724 Free PMC article. Clinical Trial.
The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
Alsaqal S, Hockings P, Ahlström H, Gummesson A, Hedström A, Hulthe J, Johansson L, Niessen HG, Schoelch C, Schultheis C, Vessby J, Wanders A, Rorsman F, Ebeling Barbier C. Alsaqal S, et al. Among authors: schoelch c. J Magn Reson Imaging. 2022 Aug;56(2):368-379. doi: 10.1002/jmri.28040. Epub 2021 Dec 25. J Magn Reson Imaging. 2022. PMID: 34953171
Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice: SHIP2 inhibition causes insulin-mimetic effects on glycogen metabolism, gluconeogenesis, and glycolysis.
Grempler R, Zibrova D, Schoelch C, van Marle A, Rippmann JF, Redemann N. Grempler R, et al. Among authors: schoelch c. Diabetes. 2007 Sep;56(9):2235-41. doi: 10.2337/db06-1660. Epub 2007 Jun 27. Diabetes. 2007. PMID: 17596404
22 results